The public awareness of the relationship between dietary lipid and the incidence of coronary heart disease has changed the consumers’ attitude towards eggs. Eggs have been singled out by diet-heart advocates as food to be avoided which has resulted in a significant reduction in egg consumption in many parts of the world. Due to the unsuccessful attempts to significantly reduce egg cholesterol content by genetic, nutritional and pharmacological tools, researchers have turned towards a more positive approach to use the egg as a vehicle for delivering to the consumers’ essential nutrients that traditionally were absent or in low concentration in the egg.
The health-promoting effects of dietary ω-3 fatty acids have provoked considerable effort to enrich animal products using various sources of ω-3 fatty acids, such as flaxseed, canola, algae or fish oils. The egg industry in particular has been very responsive in seeking new technology to exploit products beyond their traditional food value. One such technology is the Designer Egg which retains the functional, nutritional, and sensory qualities, but has a significantly altered lipid composition.
The primary goal of infant formula is to mimic the growth and development of the breast fed infant. One approach to design a formula is to match the composition of human breast milk which contains both DHA (docosahexaenoic acid) and AA (arachidonic acid). Industry and scientific community alike are searching a new oil source supplying both long chain ω -3 and ω -6 polyunsaturated fatty acids (LCPFA). Recently, we were able to elevate the amounts of DHA, still sustaining a significant level of AA in the egg but reduced ω-6 to ω-3 fatty acid ratios from 20 to 1 by feeding laying hens rations containing α-LNA (linolenic acid). The chicken egg, therefore, is a potential vehicle to provide the much needed DHA and AA, closely mimicking the fatty acid composition of human breast milk.
The objective of this paper is to share a series of studies on alpha-linolenic acid metabolism, the metabolic precursor of DHA, in the laying hen model as eggs / embryos / chick system for the maternal / neonatal nutrition study model in human, designing egg oil with ω-3 fatty acids by manipulating laying hen diets, and further applying the Designer Egg Oil to Neonatal Nutrition and Infant Food Formula. This paper focuses on the far-reaching nutritional significance of longer chain PUFA-enriched eggs (Columbus Concept Egg) containing both DHA and AA, and its wider industrial diversification as egg oil to supply much needed ω-6 to ω-3 fatty acids.
Columbus Concept Egg is known around the globe as ‘Dr. Sim’s Designer Egg’, Columbus Egg, Christopher Egg, Diet Egg, Vivian Egg, and other commercial brands. In this paper, it will be referred to as Designer Egg or DE.
抄録全体を表示